Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 577

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients: The FNCLCC PACS 01 Trial

Open access
Roché, Henri, Fumoleau, Pierre, Spielmann, Marc, Canon, Jean-Luc, Delozier, Thierry, Serin, Daniel, Symann, Michel, Kerbrat, Pierre, Soulié, Patrick, Eichler, Françoise, Viens, Patrice, Monnier, Alain, Vindevoghel, Anita, Campone, Mario, Goudier, Marie-Josèphe, Bonneterre, Jacques, Ferrero, Jean-Marc, Martin, Anne-Laure, Genève, Jean, Asselain, Bernard·2006·Journal of Clinical Oncology

Abstract

Purpose: The PACS 01 trial compared six cycles of fluorouracil, epirubicin, and cyclophosphamide (FEC) with a sequential regimen of three cycles of FEC followed by three cycles of docetaxel (FEC-D) as adjuvant treatment for women with node-positive early breast cancer. Patients and Methods: Between June 1997 and March 2000, 1,999 patients with operable node-positive breast cancer were randomly assigned to either FEC every 21 days for six cycles, or three cycles of FEC followed by three cycles of docetaxel, both given every 21 days. Hormone-receptor–positive patients received tamoxifen for 5 years after chemotherapy. The primary end point was 5-year disease-free survival (DFS). Results: Median follow-up was 60 months. Five-year DFS rates were 73.2% with FEC and 78.4% with FEC-D (unadjusted P = .011; adjusted P = .012). Multivariate analysis adjusted for prognostic factors showed an 18% reduction in the relative risk of relapse with FEC-D. Five-year overall survival rates were 86.7% with FEC and 90.7% with FEC-D, demonstrating a 27% reduction in the relative risk of death (unadjusted P = .014; adjusted P = .017). The incidence of grade 3 to 4 neutropenia, the need for hematopoietic growth factor, and incidence of nausea/vomiting were higher with FEC. Docetaxel was associated with more febrile neutropenia in the fourth cycle, stomatitis, edema, and nail disorders. Though rare overall, there were fewer cardiac events after FEC-D (P = .03), attributable mainly to the lower anthracycline cumulative dose. Conclusion: Sequential adjuvant chemotherapy with FEC followed by docetaxel significantly improves disease-free and overall survival in node-positive breast cancer patients and has a favorable safety profile.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2006.07.3916

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Cited by

See all 577

Metadata

Authors
Roché, H., Fumoleau, P., Spielmann, M., Canon, J.-L., Delozier, T., Serin, D., Symann, M., Kerbrat, P., Soulié, P., Eichler, F., Viens, P., Monnier, A., Vindevoghel, A., Campone, M., Goudier, M.-J., Bonneterre, J., Ferrero, J.-M., Martin, A.-L., Genève, J., & Asselain, B.
Venue
Journal of Clinical Oncology
Published
2006-12-20
Volume
24
Issue
36
Pages
5664-5671
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2127232551
Cited by
577
References
20
FWCI
15.33
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients: The FNCLCC PACS 01 Trial. https://app.cochat.ai/papers/10.1200/jco.2006.07.3916
The paper
Roché, H., Fumoleau, P., Spielmann, M., Canon, J.-L., Delozier, T., Serin, D., Symann, M., Kerbrat, P., Soulié, P., Eichler, F., Viens, P., Monnier, A., Vindevoghel, A., Campone, M., Goudier, M.-J., Bonneterre, J., Ferrero, J.-M., Martin, A.-L., Genève, J., & Asselain, B. (2006). Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients: The FNCLCC PACS 01 Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2006.07.3916

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.